You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner

Citation Tools

Article menu

This article has a correction. Please see:

Download PDFPDF

XML
Pathophysiology/Complications
Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Kitada M, Tsuda S, Konishi K, et al
Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner
BMJ Open Diabetes Research and Care 2017;5:e000391. doi: 10.1136/bmjdrc-2017-000391